For the interim period of the fiscal year ending March 2027, consolidated net sales were 15,119 million yen, up 13.8% year-over-year. Operating income was 1,303 million yen, down 14.1%, ordinary income was 1,727 million yen, and net income attributable to owners of the parent for the interim period was 1,195 million yen. The full-year forecast has been revised and published: net sales 29,830 million yen, operating income 1,800 million yen, ordinary income 2,500 million yen, and net income 1,780 million yen. The company operates two segments\u2014Pharmaceuticals and Building Materials\u2014with segment sales of 13,005 million yen and 2,113 million yen respectively; segment income was 1,445 million yen for Pharmaceuticals and 402 million yen for Building Materials.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4094","jir_company_name":"Nihon Kagaku Sangyo Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4094-20261109-02.pdf","jir_short_summary":"For the interim period of the fiscal year ending March 2027, consolidated net sales were 15,119 million yen, up 13.8% year-over-year. Operating income was 1,303 million yen, down 14.1%, ordinary income was 1,727 million yen, and net income attributable to owners of the parent for the interim period was 1,195 million yen. The full-year forecast has been revised and published: net sales 29,830 million yen, operating income 1,800 million yen, ordinary income 2,500 million yen, and net income 1,780 million yen. The company operates two segments\u2014Pharmaceuticals and Building Materials\u2014with segment sales of 13,005 million yen and 2,113 million yen respectively; segment income was 1,445 million yen for Pharmaceuticals and 402 million yen for Building Materials.","jir_summary":"### Overview of Results\nFor the interim period of the fiscal year ending March 2027, net sales totaled 1,511,904 thousand yen, an increase of 13.8% year-over-year. However, operating income declined due to increased investment in the recycling business and higher expenses for new business development. Ordinary income decreased slightly; despite the recognition of extraordinary gains, overall sales growth was maintained. By segment, the Pharmaceuticals business performed strongly, while the Building Materials business achieved higher sales and profits amid mixed demand and cost factors.\n\n### Outlook and Capital Allocation\nThe full-year earnings forecast has been updated: net sales are expected to be 29,830 million yen, operating income 1,800 million yen, ordinary income 2,500 million yen, and net income attributable to owners of the parent 1,780 million yen. Growth investments in new businesses such as lithium-ion battery recycling are expected to continue, though sales expansion may be affected by higher raw material costs. The financial position is stable with a shareholders' equity ratio of 83.9%, and cash flows are influenced by multiple factors including changes in interest-bearing debt.","jir_financial_highlights":"Net Sales: 15,119,038 (YoY +13.8% increase)\nOperating Income: 1,303,122 (YoY -14.1% decrease)\nOrdinary Income: 1,727,298 (YoY -0.4% decrease)\nNet Income Attributable to Owners of Parent (Interim): 1,195,672 (YoY -4.6% decrease)\nFull-year Forecast Net Sales: 29,830 (Upward revision)","jir_category":"","jir_hashtags":"#NihonKagakuSangyoCoLtdEarnings, #InterimResults, #SegmentInformation, #EarningsForecastRevision","jir_key_figures":"Net Sales: 15,119 million yen (YoY +13.8%)\nOperating Income: 1,303 million yen (YoY -14.1%)\nNet Income Attributable to Owners of Parent (Interim): 1,195 million yen (YoY -4.6%)\nFull-year Forecast: Net Sales 29,830 million yen, Operating Income 1,800 million yen, Ordinary Income 2,500 million yen, Net Income 1,780 million yen\nSegment Net Sales: Pharmaceuticals 13,005 million yen, Building Materials 2,113 million yen\nSegment Income: Pharmaceuticals 1,445 million yen, Building Materials 402 million yen","jir_meta_title":"Nihon Kagaku Sangyo Co., Ltd. Q2 FY2027 Results | Net Sales 15,119 million yen, Operating Income 1,303 million yen","jir_meta_description":"Key points of Nihon Kagaku Sangyo Co., Ltd.'s Q2 FY2027 financial summary. Net sales were 15,119 million yen, up 13.8% YoY, while operating income declined 14.1% to 1,303 million yen. Full-year outlook revised; segment trends explained.","jir_og_title":"Check Nihon Kagaku Sangyo Co., Ltd.'s Q2 FY2027 Financial Summary | Net Sales 15,119 million yen","jir_og_description":"Nihon Kagaku Sangyo Co., Ltd.'s Q2 results show higher sales year-over-year but a decline in operating income. Key points include revisions to full-year forecasts and segment-level trends.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026\/4\\\",\\\"2026\/7\\\",\\\"2026\/9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[151190,0,0]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026\/4\\\",\\\"2026\/9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[1303,1303]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Segment Net Sales Ratio\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceuticals\\\",\\\"Building Materials\\\"],\\\"datasets\\\":[{\\\"data\\\":[13005,2113]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Operating Margin\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceuticals\\\",\\\"Building Materials\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Margin\\\",\\\"data\\\":[11.2,19.0]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"table\", \"jir_chart_title\": \"Full-year Forecast Comparison\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"table\\\",\\\"data\\\":[]} \"}]","ir_related_company":17390,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-144742","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n